Targets › COX2
1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout May 2027.
Component of the cytochrome c oxidase, the last enzyme in the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from…. (UniProt, P00403)
Open in Phaseline: the race on COX2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Avidence Therapeutics | AVD275 Intra-articular Injection Cyclooxygenase (COX) inhibitor | COX1, COX2 | Phase 1 | Osteoarthritis of the Knee | May 2027 |
Osteoarthritis of the Knee (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.